Edition:
United Kingdom

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

0.67USD
8:59pm GMT
Change (% chg)

$-0.03 (-4.14%)
Prev Close
$0.70
Open
$0.70
Day's High
$0.71
Day's Low
$0.66
Volume
13,153
Avg. Vol
34,501
52-wk High
$17.76
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

Edge Therapeutics Qtrly Loss Per Share Of $0.41
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE OF $0.41.  Full Article

Edge Therapeutics Announces Updated Results From Phase 3 Newton 2 Study Of EG-1962
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE.EDGE THERAPEUTICS - IN STUDY'S PRIMARY ENDPOINT, 45% OF SUBJECTS TREATED WITH A SINGLE INTRAVENTRICULAR INJECTION OF EG-1962 EXPERIENCED A FAVORABLE OUTCOME.EDGE THERAPEUTICS - EXPECTS TO REPORT FINAL ANALYSIS OF DATA FROM ALL 283 SUBJECTS IN NEWTON 2 STUDY WHEN DATA ARE AVAILABLE LATER THIS YEAR.  Full Article

Edge Therapeutics Announces Review Of Strategic Alternatives
Monday, 30 Apr 2018 

April 30 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.EDGE THERAPEUTICS INC - BOARD OF DIRECTORS IS CONDUCTING A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING STOCKHOLDER VALUE.EDGE THERAPEUTICS INC - EDGE INTENDS TO STREAMLINE ITS OPERATIONS IN ORDER TO PRESERVE ITS CASH RESOURCES.EDGE THERAPEUTICS INC - HAS RETAINED PIPER JAFFRAY & CO. TO ACT AS ITS FINANCIAL ADVISOR TO ASSIST WITH REVIEW PROCESS.EDGE THERAPEUTICS INC - POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED/EVALUATED AS PART OF REVIEW INCLUDE ACQUISITION, MERGER.  Full Article

Edge Therapeutics Provides Update Following Interim Analysis
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS PROVIDES UPDATE FOLLOWING INTERIM ANALYSIS OF PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE.EDGE THERAPEUTICS INC - STUDY UNLIKELY TO ACHIEVE PRIMARY EFFICACY ENDPOINT; DMC RECOMMENDS DISCONTINUATION OF STUDY.EDGE THERAPEUTICS INC - NO UNEXPECTED SAFETY FINDINGS IN STUDY.EDGE THERAPEUTICS INC - EDGE TO REDUCE COSTS AND EVALUATE NEXT STEPS.EDGE THERAPEUTICS - PHASE 3 STUDY OF EG-1962 SHOWED LOW PROBABILITY OF ACHIEVING STATISTICALLY-SIGNIFICANT DIFFERENCE VERSUS STANDARD OF CARE.EDGE THERAPEUTICS - DATA MONITORING COMMITTEE RECOMMENDED STUDY BE STOPPED BASED ON CONCLUSION THAT STUDY HAS LOW PROBABILITY OF MEETING PRIMARY ENDPOINT.EDGE THERAPEUTICS - ANTICIPATES IN NEAR TERM REDUCING SCOPE OF OPERATIONS, INCLUDING SIZE OF WORKFORCE, IN ORDER TO PRESERVE CASH RESOURCES.EDGE THERAPEUTICS INC - HAS DECIDED TO DISCONTINUE NEWTON 2 STUDY.  Full Article

Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Edge Therapeutics Inc ::EDGE'S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS.EDGE THERAPEUTICS - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED PHASE 3 NEWTON 2 STUDY OF EG-1962 CONTINUE AS PLANNED.  Full Article

Edge Therapeutics reports qtrly loss per share $‍0.37​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics reports third quarter 2017 financial results.Edge Therapeutics Inc - qtrly loss per share $‍0.37​.  Full Article